NCT05583409

SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC

Effect of SBRT Combined With Osimertinib Compared With Osimertinib Alone for Stage IV Non-small Cell Lung Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Li Zhang · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with Osimertinib

Conditions

• Stage IV Non-small Cell Lung Cancer

Interventions

Type	Name	Description
RADIATION	SBRT+Osimertinib	Received SBRT after three months of Osimertinib treatment
DRUG	Osimertinib 80 MG	Osimertinib 80mg, po, Qd

Timeline

• Start date: 2023-01-01
• Primary completion: 2024-12-30
• Completion: 2025-12-30
• First posted: 2022-10-17
• Last updated: 2022-10-17

Locations

1 site across 1 country: China